CRIS Current Research Information System

PARISI, SARAH
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.303
EU - Europa 4.807
AS - Asia 2.608
AF - Africa 338
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 13
SA - Sud America 9
Totale 13.097
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.276
GB - Regno Unito 1.467
SE - Svezia 975
CN - Cina 906
IT - Italia 704
VN - Vietnam 648
DE - Germania 577
SG - Singapore 535
IN - India 246
IE - Irlanda 189
RU - Federazione Russa 182
FR - Francia 157
TG - Togo 115
ZA - Sudafrica 108
GR - Grecia 86
EE - Estonia 85
UA - Ucraina 84
JP - Giappone 76
CH - Svizzera 69
JO - Giordania 64
NG - Nigeria 57
BG - Bulgaria 55
FI - Finlandia 48
CI - Costa d'Avorio 43
BE - Belgio 34
IR - Iran 30
CA - Canada 26
KR - Corea 19
EU - Europa 18
NL - Olanda 17
TR - Turchia 16
SC - Seychelles 14
PH - Filippine 13
AT - Austria 11
HR - Croazia 11
AU - Australia 10
PL - Polonia 10
HK - Hong Kong 9
ID - Indonesia 9
RO - Romania 9
UZ - Uzbekistan 9
LT - Lituania 7
CZ - Repubblica Ceca 6
LB - Libano 6
BR - Brasile 4
ES - Italia 4
MK - Macedonia 4
MY - Malesia 4
PT - Portogallo 4
IL - Israele 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
CL - Cile 2
HU - Ungheria 2
PE - Perù 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
DK - Danimarca 1
EC - Ecuador 1
GE - Georgia 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
NO - Norvegia 1
PA - Panama 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
UG - Uganda 1
Totale 13.097
Salva come PNG Salva come JPEG
Città #
Southend 1.379
Chandler 630
Fairfield 502
Singapore 467
Ashburn 396
Dong Ket 368
Ann Arbor 299
Houston 292
Wilmington 282
Woodbridge 259
Princeton 234
Santa Clara 226
Seattle 221
Dublin 188
Cambridge 182
Bologna 164
Boardman 153
Beijing 133
Westminster 117
Lomé 115
Nanjing 111
Padova 104
Medford 84
New York 73
Amman 64
Jinan 63
Bern 61
Abeokuta 57
Sofia 55
Berlin 53
Redwood City 50
Shenyang 48
Helsinki 46
Milan 46
Saint Petersburg 44
Abidjan 43
Bremen 42
Nanchang 41
Tokyo 41
Hebei 40
Turin 34
Brussels 33
Florence 32
Changsha 29
Tianjin 28
Jiaxing 26
San Diego 26
Zhengzhou 25
Grafing 23
Falls Church 22
Frankfurt am Main 22
Jacksonville 21
Guangzhou 17
Norwalk 15
Rome 15
Athens 14
Istanbul 14
Los Angeles 14
Mountain View 14
Paris 14
Redmond 14
Davao City 13
Haikou 13
Mahé 13
Ningbo 13
North York 13
Shanghai 13
Dearborn 12
Taiyuan 12
Taizhou 12
Hyderabad 11
Leawood 11
Yubileyny 11
Fuzhou 10
Hangzhou 10
Riolo Terme 10
Wuhan 10
Mülheim 9
Andover 8
Faenza 8
Hong Kong 8
Jakarta 8
Kunming 8
Toronto 8
Vienna 8
Augusta 7
Bühl 7
Chengdu 7
Lanzhou 7
Olalla 7
Phoenix 7
Tehran 7
Qingdao 6
Shijiazhuang 6
Zanjan 6
Amsterdam 5
Busseto 5
Chicago 5
Des Moines 5
Frankfurt Am Main 5
Totale 8.569
Salva come PNG Salva come JPEG
Nome #
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 233
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 220
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 218
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 212
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 198
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 190
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 189
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 188
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 186
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 180
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 177
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 175
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 163
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 157
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 157
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 156
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 155
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 154
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 153
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 151
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 148
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 147
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 147
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 138
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 136
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 135
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 132
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 132
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 131
Immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: Time for a biology-driven approach 131
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 130
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 129
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 128
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 128
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 127
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 127
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 127
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 126
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 126
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 125
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 125
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 124
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 123
The more, the better: "Do the right thing" for natural killer immunotherapy in acute myeloid leukemia 123
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 123
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 123
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 123
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 122
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 122
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 118
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 116
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 116
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 113
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 112
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 112
SNP array reveals a new deletion of JAK2 in AML patients 111
The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. 111
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 110
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 109
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 109
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 109
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 109
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 108
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 108
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 108
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 106
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 105
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 104
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 103
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 102
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 102
Patient with ataxia telangiectasia who developed acute myeloid leukemia. 101
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 101
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 100
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 98
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 97
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 97
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 97
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 96
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 94
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 93
null 93
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 92
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 92
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 91
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 90
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 88
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 88
A phase I study of Tipifarnib and Bortezomib in the treatment of poor risk adult acute myeloid leukemia (AML) 88
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 87
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 87
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 87
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 87
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 85
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 83
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 81
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 81
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 79
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 78
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 77
Totale 12.379
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.097
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.097
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.498 0 0 0 0 0 0 309 301 387 188 183 130
2020/20211.834 295 63 24 36 62 85 39 153 173 85 88 731
2021/20222.503 225 55 166 278 254 136 54 162 126 182 436 429
2022/20232.819 314 456 123 358 234 233 94 178 439 54 192 144
2023/2024783 37 111 37 93 64 170 40 40 44 55 56 36
2024/20251.535 127 417 231 195 323 105 137 0 0 0 0 0
Totale 13.430